Strategies to identify hepatitis C virus infection in patients receiving anticancer therapy: a cross-sectional study.

ABSTRACT:

Background

Optimal hepatitis C virus (HCV) screening strategies for cancer patients have not been established. We compared the performance of selective HCV screening strategies.

Methods

We surveyed patients presenting for first systemic anticancer therapy during 2013-2014 for HCV risk factors. We estimated the prevalence of positivity for HCV antibody (anti-HCV) and examined factors associated with anti-HCV status using Fisher's exact test or Student's t test. Sensitivity was calculated for screening patients born during 1945-1965, patients with ≥ 1 other risk factor, or both cohorts ("combined screening").

Results

We enrolled 2122 participants. Median age was 59 years (range, 18-91); 1138 participants were women. Race/ethnicity distribution was white non-Hispanic, 76

SUBMITTER: Torres HA 

PROVIDER: S-EPMC9706509 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature